Physician profile
Michael D Abbott
NPI 1720038573
$1,049.34
in general payments reported to CMS, 2019-2025
10 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.68 · 2020: $88.46 · 2021: $81.23 · 2022: $124 · 2023: $40.11 · 2024: $147 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $294.82 | 2022-2025 | |
| Biotissue Holdings INC. | $192.09 | 2025 | |
| Alcon Vision LLC | $172.28 | 2020-2024 | Precision 1, Total30 |
| Johnson & Johnson Vision Care, INC. | $125.49 | 2020-2025 | Acuvue |
| Glaukos Corporation | $110.44 | 2025 | Photrexa Viscous and Photrexa |
| Bausch & Lomb Americas INC. | $38.83 | 2025 | Infuse |
| Kala Pharmaceuticals, INC. | $35.79 | 2019-2021 | |
| Allergan, INC. | $31.03 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $25.53 | 2025 | Xdemvy |
| Coopervision INC. | $23.04 | 2024 | Biofinity Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.